Sector consensus Charles River Laboratories International, Inc.
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
NYSE
21:00:03 04/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 288.50 USD | -1.65% |
|
-1.03% | +44.63% |
| 08-20 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| 08-20 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 281 | -2.6% | 14 | ||||||
| 686 | +20.94% | 23 | ||||||
| 250.46 | +19.26% | 20 | ||||||
| 276.28 | +3.18% | 18 | ||||||
| 432.16 | +20.63% | 28 | ||||||
| 267,626.15 | +42.28% | 22 | ||||||
| 270.77 | +16.3% | 20 | ||||||
| 581.83 | -1.6% | 12 | ||||||
| 72.53 | -0.26% | 14 | ||||||
| 185.56 | +12.56% | 16 | ||||||
| 67.47 | +4.41% | 15 | ||||||
| 70.73 | -2.35% | 11 | ||||||
| 138.97 | +42.39% | 6 | ||||||
| 49.79 | +20.88% | 11 | ||||||
| 638.68 | +81.54% | 19 | ||||||
| 134.71 | +14.76% | 21 | ||||||
| 88.14 | +51.72% | 22 | ||||||
| 174.69 | +19.88% | 13 | ||||||
| 46.07 | +5.98% | 14 | ||||||
| 3.83 | -4.54% | 7 | ||||||
| Average | 13,603.79 | +18.27% | 16 | ||||||
| Weighted average by Cap. | 23,396.38 | +18.06% | 19 |
Select your edition
All financial news and data tailored to specific country editions
